{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:08:01Z","timestamp":1789038481926,"version":"build-2803163510"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>This Clinical Insights discusses the diagnosis and management of adverse effects of antiamyloid therapies and what medications require consideration or avoidance.<\/jats:p>","DOI":"10.1001\/jamainternmed.2025.2242","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:31:08Z","timestamp":1750678268000},"page":"1029","source":"Crossref","is-referenced-by-count":1,"title":["New Frontier, New Challenges\u2014Recognizing and Managing Adverse Effects of Antiamyloid Therapies"],"prefix":"10.1001","volume":"185","author":[{"given":"Megan A.","family":"Rech","sequence":"first","affiliation":[{"name":"Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines Jr VA Hospital, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelum T.","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences, Rush Alzheimer\u2019s Disease Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ula","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, New York University Grossman School of Medicine, New York, New York"},{"name":"Geriatric Research, Education and Clinical Center, James J. Peters VA Medical Center, New York, New York"},{"name":"Department of Population Health, New York University Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"iit250005r1","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-024-03340-9","article-title":"Lifetime risk and projected burden of dementia.","volume":"31","author":"Fang","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"iit250005r2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease.","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"iit250005r3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"11","key":"iit250005r4","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","article-title":"Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.","volume":"146","author":"Hampel","year":"2023","journal-title":"Brain"},{"issue":"1","key":"iit250005r5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/alz.12366","article-title":"Prevalence of cerebral amyloid angiopathy: a systematic review and meta-analysis.","volume":"18","author":"J\u00e4kel","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"3","key":"iit250005r6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","article-title":"Lecanemab: appropriate use recommendations.","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"iit250005r7","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/STR.0000000000000480","article-title":"Vascular neurology considerations for antiamyloid immunotherapy: a science advisory from the American Heart Association.","volume":"56","author":"Greenberg","year":"2025","journal-title":"Stroke"},{"issue":"5","key":"iit250005r8","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/jcm13051245","article-title":"The impact of anti-amyloid immunotherapies on stroke care.","volume":"13","author":"Bilodeau","year":"2024","journal-title":"J Clin Med"},{"issue":"5","key":"iit250005r9","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1056\/NEJMc2215907","article-title":"Response to: multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke.","volume":"388","author":"Sabbagh","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"iit250005r10","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease.","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res Ther"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2835619\/jamainternal_rech_2025_it_250005_1753201878.27615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T15:00:41Z","timestamp":1754319641000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2835619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.2242","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}